TGTX Q1 2022 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+154.2% YoY

Gross Profit

$2M88.2% margin

Operating Income

-$67M-3317.1% margin

Net Income

-$69M-3423.3% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-13.1%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$303M

Total Liabilities

$133M

Stockholders' Equity

$170M

Cash & Equivalents

$186M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$793,000	+154.2%
Gross Profit	$2M	$654,000	+172.0%
Operating Income	-$67M	-$89M	+25.0%
Net Income	-$69M	-$91M	+23.9%

Revenue Segments

Product revenue, net

$2M98%

License revenue

$38,0002%